Health Care · Pharmaceutical Preparations

ORIC Oric Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 179628083 filings
Russell 2000

ORIC at a glance

Oric Pharmaceuticals, Inc. (ORIC, SEC CIK 1796280) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Oric Pharmaceuticals, Inc. (ORIC) shares worth $555.2 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Piscitelli Dominic on October 20, 2026 of 14,000 shares at $13.53 per share.
  • In the last 90 days, ORIC insiders reported 0 open-market purchases ($0) and 7 open-market sales ($1.5M) on Form 4, a net sale of $1.5M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 7 sells
Net −$1.5M
13F holders
27 funds
$555.2M · +1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product candidates commercialized
  • Net loss $48.1M vs $32.6M YoY, operating expenses $51.6M vs $36.7M
  • Rinzimetostat R&D $21.2M, up $15.6M YoY, largest program spending
  • Operating cash use $106.0M, cash and investments sufficient into second half of 2028
  • Himalayas-1 Phase 3 underway, Redwood-1 planned first half of 2027, funding needs and development costs rising

Risk Factors

  • New regulatory risk: 2026 FDA workforce reductions and policy changes could delay reviews, inspections, and regulatory correspondence
  • Most materially updated compliance risk: CMS proposed 2029 Medicare negotiation rules, increasing uncertainty over future drug pricing
  • Operational risk: Competitors’ greater AI use in pharmaceutical development could disadvantage ORIC’s limited AI adoption
  • Financial risk: $345.4 million in cash, equivalents, and investments expected to fund operations into the second half of 2028
  • Legal risk: EU GDPR violations could trigger fines up to €20,000,000 or 4% of worldwide annual turnover

AI summary of the ORIC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Oric Pharmaceuticals’ financial results for quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for earnings figures, cash position and operational updates

Item EX-99.1: Item EX-99.1

  • Rinzimetostat Phase 3 Himalayas-1 initiated in approximately 600 post-abiraterone mCRPC patients, with Bayer supplying NUBEQA at no cost
  • Preliminary rPFS remained competitive with mevrometostat: 10-month rates 59% post-abiraterone and 59% post-AR inhibitor
Filed Oct 23, 2026Full analysis →

Item 8.01: Other Events

  • Phase 1b efficacy: 84% investigator ORR and 80% BICR ORR across 25 response-evaluable patients
  • Intracranial activity: 67% BICR RANO-BM ORR and 40% complete response rate across 15 patients

Item EX-99.1: Item EX-99.1

  • Phase 1b data support rapid advancement toward Phase 3 in first-line EGFR atypical NSCLC
  • Systemic confirmed ORR 84%, BICR ORR 80%, and 6-month PFS 88% in 25 evaluable patients

Item 7.01: Regulation FD Disclosure

  • Enozertinib (ORIC-114) program update presented at ESMO Congress 2026 on October 23, 2026
  • Exhibit 99.1 contains the disclosed clinical data, relevant to assessing enozertinib’s development progress
Filed Aug 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 3 Himalayas-1 initiated in approximately 600 mCRPC patients across 25 countries, materially advancing rinzimetostat toward registration
  • Bayer supplying NUBEQA at no cost, preserving ORIC’s full global rights while reducing trial drug-supply expense

Item 2.02: Results of Operations and Financial Condition

  • Press release announces ORIC Pharmaceuticals’ financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary

AI summaries of ORIC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ORIC

Don't miss the next ORIC filing

  • Alerts as it files. A push when ORIC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ORIC, by share count.
  • Ask anything. An AI agent that reads every ORIC filing and answers with sources.

ORIC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Piscitelli DominicSellOct 20, 2026$13.53
Piscitelli DominicMOct 20, 2026$4.36
Piscitelli DominicMOct 20, 2026-
Heyman Richard A.SellOct 1, 2026$12.91
Heyman Richard A.SellOct 1, 2026$12.91
Heyman Richard A.MOct 1, 2026$1.60
Heyman Richard A.MOct 1, 2026-
Piscitelli DominicMSep 28, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$110.8M-$142.9M-$143.0M
Net Income-$100.7M-$127.8M-$129.5M
Balance Sheet
Total Assets$252.0M$274.1M$408.9M
Equity$224.1M$243.1M$384.4M
ROE-44.9%-52.6%-33.7%
Per Share
EPS$-1.96$-1.83$-1.47
Cash Flow
Operating CF-$85.7M-$112.7M-$111.0M
CapEx-$1.2M$712K

Source: XBRL data in Oric Pharmaceuticals, Inc. (ORIC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ORIC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ORIC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$555.2M
Q2 202626$515.0M
Q1 202626$550.1M
Q4 202523$347.0M
Q3 202524$463.7M
Q2 202526$334.6M
Q1 202523$133.5M
Q4 202418$162.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ORIC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
10-QNov 16, 2026Analysis
8-KOct 23, 2026Analysis-
4Oct 21, 2026--
4Oct 2, 2026--
4Sep 29, 2026--
4Sep 25, 2026--
4Aug 28, 2026--
10-QAug 3, 2026Analysis
8-KAug 3, 2026Analysis-
8-KJul 30, 2026Analysis-
4Jul 28, 2026--
4Jul 8, 2026--
8-KJun 22, 2026Analysis-
SC 13GMay 15, 2026-
10-QMay 4, 2026Analysis
8-KMay 4, 2026Analysis-
8-KMar 31, 2026--
4Feb 26, 2026--
8-KFeb 23, 2026Analysis-
10-KFeb 23, 2026-
8-KFeb 23, 2026Analysis-
SC 13GJan 21, 2026-
4Jan 20, 2026-
4Jan 6, 2026-

Related Health Care companies

All Health Care →

ORIC SEC filings: frequently asked questions

Are ORIC insiders buying or selling?

In the last 90 days, Oric Pharmaceuticals, Inc. (ORIC) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $1.5 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ORIC stock?

As of September 30, 2026, the largest Oric Pharmaceuticals, Inc. (ORIC) holders among the 13F filers tracked by SignalX were BlackRock ($94.0 million), T. Rowe Price Group ($68.5 million), State Street Corp ($55.6 million), Vanguard Capital Management LLC ($54.9 million), Viking Global Investors ($48.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ORIC report in its latest 8-K?

Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Oric Pharmaceuticals’ financial results for quarter ended September 30, 2026.

What are the latest ORIC SEC filings?

Oric Pharmaceuticals, Inc. (ORIC) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 21, 2026.

What is ORIC's SEC CIK number?

Oric Pharmaceuticals, Inc. (ORIC)'s SEC Central Index Key (CIK) is 1796280. EDGAR lists every ORIC filing under that number.

Ask anything about ORIC

The research agent reads ORIC's filings, financials, insider trades and 13F holders, then answers with sources.